Castleark Management LLC Purchases Shares of 358,880 Elanco Animal Health Incorporated $ELAN

Castleark Management LLC acquired a new stake in Elanco Animal Health Incorporated (NYSE:ELAN) in the second quarter, HoldingsChannel reports. The institutional investor acquired 358,880 shares of the company’s stock, valued at approximately $8,832,000.

Several other institutional investors have also made changes to their positions in ELAN. BlackRock Inc. bought a new position in shares of Elanco Animal Health during the second quarter valued at $1,202,198,000. Peak Retirement Planning Inc. bought a new stake in shares of Elanco Animal Health in the 4th quarter worth about $2,756,000. Norges Bank acquired a new stake in shares of Elanco Animal Health during the 4th quarter worth about $32,415,000. Allspring Global Investments Holdings LLC acquired a new position in Elanco Animal Health in the first quarter valued at about $66,390,000. Finally, Sei Investments Co. increased its holdings in shares of Elanco Animal Health by 737.5% during the first quarter. Sei Investments Co. now owns 5,650,393 shares of the company’s stock worth $135,214,000 after buying an additional 4,975,721 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently commented on ELAN shares. Wall Street Zen downgraded Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. UBS Group increased their target price on Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Morgan Stanley raised their target price on Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 22nd. Weiss Ratings downgraded shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, August 20th. Finally, Piper Sandler reissued an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Elanco Animal Health has a consensus rating of “Moderate Buy” and an average price target of $29.09.

Elanco Animal Health Trading Up 2.8%

ELAN stock opened at $25.11 on Wednesday. The company has a market cap of $12.55 billion, a P/E ratio of -61.25, a PEG ratio of 1.46 and a beta of 1.67. Elanco Animal Health Incorporated has a twelve month low of $17.11 and a twelve month high of $27.98. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. The business has a fifty day moving average of $24.58 and a 200-day moving average of $24.01.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. The firm had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The company’s revenue was up 10.2% on a year-over-year basis. During the same period last year, the company earned $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, equities research analysts expect that Elanco Animal Health Incorporated will post 1.12 EPS for the current year.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, insider Shiv O’neill acquired 3,998 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were acquired at an average cost of $23.58 per share, for a total transaction of $94,272.84. Following the completion of the acquisition, the insider directly owned 87,832 shares of the company’s stock, valued at approximately $2,071,078.56. This represents a 4.77% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Paul Herendeen acquired 10,000 shares of Elanco Animal Health stock in a transaction on Friday, August 7th. The stock was acquired at an average cost of $23.68 per share, for a total transaction of $236,800.00. Following the completion of the purchase, the director owned 111,687 shares of the company’s stock, valued at approximately $2,644,748.16. The trade was a 9.83% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 63,198 shares of company stock valued at $1,473,109 over the last 90 days. Company insiders own 1.14% of the company’s stock.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.